ANKRD29 and non-small cell lung carcinoma: And we revealed that ANKRD29 could be involved in tumor microenvironment (TME) and served as a promising biomarker of immune checkpoint blockers (ICBs) therapy in NSCLC by integrative bioinformatical analysis and T cell killing assays.